Detalhe da pesquisa
1.
Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation
Braz. j. med. biol. res
; 50(2): e5566, 2017. tab, graf
Artigo
em Inglês
| LILACS | ID: biblio-839257